Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Easy bruising is one of the most common and usually expected side effects of Eliquis (apixaban), because the medication reduces your blood's ability to clot and small bumps that once went unnoticed now show up as visible marks. However, not all bruising is harmless: large or rapidly spreading bruises, bruises that appear with no known injury, swelling and pain under the skin, or bruising alongside nosebleeds, bleeding gums, pink or brown urine, black or tarry stools, severe headache, dizziness, or unusual weakness can point to dangerous internal bleeding that needs urgent evaluation. Certain factors also raise your risk, including higher doses, older age, kidney problems, low platelets, alcohol use, and combining Eliquis with aspirin, NSAIDs, other blood thinners, or some antidepressants and antifungals. There are important differences between normal bruising and warning-sign bruising, and specific timing rules for when to call your prescriber versus seek emergency care, so see below to understand more before you assume your symptoms are routine.
Because bruising on a blood thinner sits on a spectrum from expected to emergency, the safest next step is to get your specific pattern of symptoms sorted quickly rather than guessing, and a free, instant, online symptom check can help you clarify what your bruising and any other signs may mean and what to do next.
Last reviewed for medical accuracy: 09/12/2026
Eliquis (apixaban) is a widely used anticoagulant prescribed to reduce the risk of stroke and blood clots. Like all blood-thinners, it carries the potential for bleeding-related side effects. One of the most commonly reported issues is easy bruising. Below, we break down why this happens, when you can expect it, and when it may signal a more serious concern.
Eliquis works by inhibiting specific clotting factors in your blood. This helps prevent dangerous clots but also makes it easier to bleed:
Most people on Eliquis notice more bruises than before starting treatment. In many cases, these bruises are small, painless, and resolve on their own within one to two weeks.
You may experience mild bruising without it indicating a serious problem. Characteristics of normal bruising include:
Tips to manage mild bruising:
While mild bruising is expected, certain warning signs suggest a more serious bleed or a complication of Eliquis. Seek medical attention if you notice:
If you experience any of these, call your healthcare provider right away or go to the nearest emergency department. Severe bleeding can be life-threatening if not treated promptly.
Certain conditions and medications can amplify “eliquis side effects,” including bruising and bleeding:
Be sure to tell your doctor about all prescription medications, over-the-counter drugs, and supplements you take.
You can take proactive steps to reduce the risk of serious bruising or bleeding:
Even if bruising seems mild, it’s wise to stay vigilant. If you ever feel unsure, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you decide if your symptoms warrant a call to your doctor or a visit to the emergency room.
Always contact your healthcare provider if you notice any of the following:
Eliquis side effects are a trade-off for its powerful stroke and clot-prevention benefits. For most people, the prevention of potentially fatal blood clots outweighs the inconvenience of mild bruising. Your doctor has prescribed Eliquis because they believe the benefits exceed the risks in your particular case.
That said, it’s always important to:
If you have any doubt about your bruising or other symptoms, speak to a doctor. Early evaluation can prevent minor issues from becoming serious complications. Remember: when it matters most, prompt medical advice saves lives.
(References)
* Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI, AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8. PMID: 23216615.
* Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1. PMID: 23808982.
* Birnie DH, Healey JS, Wells GA, Ayala-Paredes F, Coutu B, Sumner GL, Becker G, Verma A, Philippon F, Kalfon E, Eikelboom J, Sandhu RK, Nery PB, Lellouche N, Connolly SJ, Sapp J, Essebag V. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). Eur Heart J. 2018 Nov 21;39(44):3973-3979. doi: 10.1093/eurheartj/ehy413. PMID: 30462279.
* McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020 Feb;18(2):411-421. doi: 10.1111/jth.14662. Epub 2019 Nov 28. PMID: 31630479.
* Kuno T, Takagi H, Ando T, Sugiyama T, Miyashita S, Valentin N, Shimada YJ, Kodaira M, Numasawa Y, Briasoulis A, Burger A, Bangalore S. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. J Am Coll Cardiol. 2020 Jan 28;75(3):273-285. doi: 10.1016/j.jacc.2019.10.059. PMID: 31976865.
* Ballestri S, Romagnoli E, Arioli D, Coluccio V, Marrazzo A, Athanasiou A, Di Girolamo M, Cappi C, Marietta M, Capitelli M. Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review. Adv Ther. 2023 Jan;40(1):41-66. doi: 10.1007/s12325-022-02333-9. Epub 2022 Oct 16. PMID: 36244055; PMCID: PMC9569921.
* Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, Bansal N, Gadegbeku CA, Garcia DA, Garonzik S, Lopes RD, Mahaffey KW, Matsuda K, Middleton JP, Rymer JA, Sands GH, Thadhani R, Thomas KL, Washam JB, Winkelmayer WC, Granger CB, RENAL-AF Investigators. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation. 2022 Dec 6;146(23):1735-1745. doi: 10.1161/CIRCULATIONAHA.121.054990. Epub 2022 Nov 6. PMID: 36335914.
* Payne RM, Burns KM, Glatz AC, Male C, Donti A, Brandão LR, Balling G, VanderPluym CJ, Bu'Lock F, Kochilas LK, Stiller B, Cnota JF 2nd, Rahkonen O, Khan A, Adorisio R, Stoica S, May L, Burns JC, Saraiva JFK, McHugh KE, Kim JS, Rubio A, Chía-Vazquez NG, Meador MR, Dyme JL, Reedy AM, Ajavon-Hartmann T, Jarugula P, Carlson-Taneja LE, Mills D, Wheaton O, Monagle P. Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease. J Am Coll Cardiol. 2023 Dec 12;82(24):2296-2309. doi: 10.1016/j.jacc.2023.10.010. PMID: 38057072.
* Fredman D, McNeil R, Eldar O, Leader A, Gafter-Gvili A, Avni T. Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies. J Thromb Thrombolysis. 2024 Mar;57(3):453-465. doi: 10.1007/s11239-023-02926-3. Epub 2023 Dec 21. PMID: 38127261.
* Castellucci LA, Chen VM, Kovacs MJ, Lazo-Langner A, Greenstreet P, Kahn S, Côté B, Schulman S, de Wit K, Douketis J, Suryanarayan D, Wan T, Yeo E, Le Templier G, Tran HA, Willcox A, Crowther HJ, Prasad R, Shivakumar S, Umana E, Ni Ainle F, Tritschler T, Barco S, Galanaud JP, Blondon M, Baumann Kreuziger L, Solymoss S, Kearon C, Thomas E, Ramsay T, Le Gal G, Rodger M, COBRRA Trial Investigators. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism. N Engl J Med. 2026 Mar 12;394(11):1051-1060. doi: 10.1056/NEJMoa2510703. PMID: 41812192.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.